Healios K.K.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HLOSF research report →
About the company
Healios K. K. is a biotechnology firm specializing in the innovation, development, production, and commercialization of cell therapy and regenerative medicine products, with operations spanning Japan, Europe, and the United States.
- CEO
- Tadahisa S. Kagimoto
- IPO
- 2020
- Employees
- 65
- HQ
- Tokyo, JP
Price Chart
- Market Cap
- $193.79M
- P/E
- -10.34
- P/S
- 363.72
- P/B
- 4.17
- EV/EBITDA
- -9.75
- Div Yield
- 0.00%
- Gross Margin
- -529.73%
- Op Margin
- -5113.51%
- Net Margin
- -4235.14%
- ROE
- -75.40%
- ROIC
- -20.69%
- Revenue
- $104.09M · -81.41%
- Net Income
- $-2,218,934,580 · 47.60%
- EPS
- $-20.59 · 56.99%
- Op Income
- $-3,405,969,498
- FCF YoY
- -57.06%
- 52W High
- $4.45
- 52W Low
- $1.80
- 50D MA
- $1.97
- 200D MA
- $2.51
- Beta
- 1.43
- Avg Volume
- 30
Get TickerSpark's AI analysis on HLOSF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our HLOSF coverage
Recent articles, reports, and earnings notes.
No research on HLOSF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate HLOSF report →Similar companies
Peers in the same neighborhood.